双鹭药业(002038) - 2019 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2019 was ¥465,621,600.26, representing a 5.79% increase compared to ¥440,127,601.59 in the same period last year[9]. - Net profit attributable to shareholders for Q1 2019 was ¥200,556,922.20, up 9.98% from ¥182,362,771.17 in the previous year[9]. - Basic earnings per share for Q1 2019 were ¥0.2928, a 9.95% increase from ¥0.2663 in the same period last year[9]. - The company's net profit for the current period is 198,348,653.59, an increase from 181,042,339.31 in the previous period, representing a growth of approximately 9.1%[56]. - Operating revenue reached 465,022,711.65, compared to 436,560,472.09 in the previous period, indicating a growth of about 6.5%[60]. - The total profit for the current period is 224,970,456.02, compared to 208,276,290.06 in the previous period, showing an increase of approximately 8.1%[56]. - The total comprehensive income for the current period is 195,465,576.96, up from 177,940,372.12, which is an increase of around 9.1%[59]. Cash Flow - The net cash flow from operating activities increased by 35.40%, reaching ¥210,979,582.78 compared to ¥155,814,084.75 in Q1 2018[9]. - Operating cash inflow for the current period was CNY 522,666,752.32, an increase from CNY 505,742,572.55 in the previous period, reflecting a growth of approximately 3.0%[70]. - The company reported a cash inflow from operating activities of CNY 522,354,044.57, which is an increase from CNY 498,628,956.13, reflecting a growth of about 4.0%[76]. - Cash outflow from investing activities totaled CNY 74,483,089.44, compared to CNY 328,470,818.40 in the previous period, showing a decrease of approximately 77.3%[73]. - The company experienced a net increase in cash and cash equivalents of CNY 156,762,888.50, compared to CNY 10,745,159.70 in the previous period, showing a substantial increase of approximately 1,460.5%[79]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,190,090,538.49, reflecting a 4.05% increase from ¥4,988,274,393.14 at the end of the previous year[9]. - The total liabilities decreased to approximately 453.70 million yuan from 469.73 million yuan at the end of the previous year[39]. - The total equity attributable to shareholders of the parent company was CNY 4,711,585,438.46, compared to CNY 4,514,351,333.56, indicating an increase of 4.4%[52]. - The company reported a decrease in total liabilities to CNY 398,262,108.62 from CNY 408,537,536.05, a reduction of 2.8%[49]. - Cash and cash equivalents increased to CNY 1,203,618,243.00 from CNY 1,046,855,354.50, marking a growth of 15%[43]. Shareholder Information - The top two shareholders, Xu Mingbo and Xinxing Bailu Investment Group Co., Ltd., held 22.57% and 20.63% of shares, respectively[13]. - The total number of ordinary shareholders at the end of the reporting period was 43,123[13]. Expenses - Total operating costs amounted to CNY 266,900,034.03, up from CNY 242,741,895.05, reflecting a year-over-year increase of 9.9%[53]. - Management expenses increased by 152.46% year-on-year, primarily due to the increase in intangible assets and corresponding amortization[20]. - Research and development expenses were CNY 22,397,212.53, down from CNY 25,906,447.33, a decrease of 13%[53]. - Research and development expenses increased significantly to 22,627,600.66 from 9,296,381.02, reflecting a rise of approximately 143.5%[60]. Investment and Income - Investment income increased by 218.43% year-on-year, mainly due to growth in financial management income and dividends from invested companies[20]. - The company recorded investment income of 13,595,126.82, compared to 4,338,038.27 in the previous period, representing a significant increase of approximately 213.5%[60]. - The company had a weighted average return on equity of 4.36%, up from 4.18% in the previous year[9]. Other Financial Metrics - Non-recurring gains and losses totaled ¥17,902,004.30 for the reporting period[9]. - Impairment losses on assets increased by 64.62% year-on-year, mainly due to the aging of accounts receivable and corresponding increases in bad debt provisions[20]. - Fair value changes in financial assets increased by 157.95% year-on-year, primarily due to an increase in stock market values[20]. - The income tax expense decreased to 26,621,802.43 from 27,233,950.75, reflecting a reduction of about 2.3%[56]. - The company reported a foreign exchange loss of -2,883,076.63, slightly improved from -3,101,967.19 in the previous period[59].